share_log

Lyell Immunopharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals(Amendment)-Foresite Capital Fund IV, L.P. (“FCF IV”)(4.0%),Foresite Capital Management IV, LLC (“FCM IV”)(4.0%), etc.

Lyell Immunopharma | SC 13G/A:超過5%持股股東披露文件(修正)-Foresite Capital Fund IV, L.P. (“FCF IV”)(4.0%),Foresite Capital Management IV, LLC (“FCM IV”)(4.0%)等

2023/02/13 17:02
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息